PDRN for Tear Troughs: How It Works, Evidence & Treatment Options

How PDRN Targets Tear Troughs

PDRN addresses tear trough concerns through tissue quality improvement rather than volumetric augmentation. The periorbital skin is uniquely thin and has minimal subcutaneous fat, meaning that even modest improvements in dermal thickness and quality can produce visible changes in tear trough appearance. PDRN's activation of fibroblasts through the adenosine A2A receptor stimulates collagen and glycosaminoglycan production in the periorbital dermis, gradually increasing dermal thickness and density. This thicker, denser dermis reduces the translucency that allows dark vascular structures beneath to show through — a major contributor to the dark, hollow appearance of prominent tear troughs. PDRN-stimulated angiogenesis improves microcirculation in the periorbital area, which is often compromised due to the region's thin skin and limited vascular supply. Better microcirculation reduces the venous stasis (blood pooling) that contributes to dark circles within the tear trough. The anti-inflammatory properties of PDRN are also relevant because chronic low-grade inflammation in the periorbital area contributes to tissue degradation and edema that worsen tear trough appearance. Products like Rejuran I (eye-specific formulation) are designed specifically for periorbital injection with a lower viscosity optimized for the thin skin of this area.

Conventionally, tear troughs have been treated primarily with hyaluronic acid (HA) dermal fillers to volumize the depression. While effective, HA fillers in the tear trough carry specific risks including the Tyndall effect (bluish discoloration from superficially placed filler), lumps and irregularities in the thin periorbital skin, migration, and lymphatic obstruction causing persistent puffiness. These complications are common enough that tear trough filler has developed a reputation as one of the highest-risk filler zones.

PDRN offers a fundamentally different approach to tear trough improvement. Rather than adding exogenous volume, PDRN stimulates the body's own tissue regeneration — thickening the thin periorbital skin by promoting collagen and extracellular matrix production, improving the quality and vascularity of the tissue, and reducing the dark discoloration caused by dermal thinning that allows underlying vasculature to show through. This biological approach avoids the volumetric complications associated with fillers while addressing the tissue quality deterioration that contributes to tear trough visibility.